MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q4
hinzugefügt 03.03.2026
Agilent Technologies Langfristige Verbindlichkeiten 2011-2026 | A
Langfristige Verbindlichkeiten Jährlich Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 3.29 B | 2.62 B | 2.8 B | 2.33 B | 2.61 B | 2.33 B | 3.83 B | 3.8 B | 3.46 B | 2.9 B |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 3.83 B | 2.33 B | 3 B |
Langfristige Verbindlichkeiten anderer Aktien in der Diagnostik & Forschung
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
7.58 M | $ 13.65 | -0.44 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
238 M | $ 8.87 | 2.9 % | $ 591 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
2.35 B | $ 151.97 | -2.34 % | $ 7.53 B | USA |
 |
Castle Biosciences
CSTL
|
2.76 M | $ 25.83 | 1.06 % | $ 717 M | USA |
 |
CareDx, Inc
CDNA
|
17.9 M | $ 17.32 | 1.82 % | $ 923 M | USA |
 |
DexCom
DXCM
|
1.15 B | $ 66.34 | 3.27 % | $ 25.9 B | USA |
 |
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
981 M | $ 103.85 | 0.27 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
559 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
2.26 M | $ 14.95 | 1.22 % | $ 452 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
62.1 M | $ 17.29 | -3.3 % | $ 2.24 B | USA |
 |
Guardant Health
GH
|
91.4 M | $ 87.18 | 1.98 % | $ 10.9 B | USA |
 |
Anixa Biosciences
ANIX
|
4.17 M | $ 2.84 | 0.35 % | $ 92.2 K | USA |
 |
Danaher Corporation
DHR
|
26.9 B | $ 191.39 | 2.17 % | $ 136 B | USA |
 |
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
461 M | $ 97.61 | -0.73 % | $ 8.05 B |  Irlanda |
 |
IQVIA Holdings
IQV
|
13 B | $ 164.89 | 0.1 % | $ 28.3 B | USA |
 |
Illumina
ILMN
|
2.04 B | $ 119.28 | 0.29 % | $ 19 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 198.94 | -0.38 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.58 B | - | - | $ 10.6 B |  Niderland |
 |
BioNano Genomics
BNGO
|
16.4 M | $ 1.11 | - | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
25.8 M | $ 8.42 | -6.44 % | $ 239 M | Israel |
 |
Lantheus Holdings
LNTH
|
225 M | $ 78.5 | -1.25 % | $ 5.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
3.56 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
73.8 M | $ 453.64 | 0.72 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
1.61 B | $ 1 198.71 | 2.13 % | $ 24.7 B |  Schweiz |
 |
Celcuity
CELC
|
69.2 K | $ 114.9 | 0.6 % | $ 4.53 B | USA |
 |
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | USA |
 |
Neogen Corporation
NEOG
|
19.6 M | $ 9.11 | 0.22 % | $ 1.98 B | USA |
 |
National Research Corporation
NRC
|
39.6 M | $ 17.4 | 5.33 % | $ 389 M | USA |
 |
NeoGenomics
NEO
|
435 M | $ 8.24 | 4.57 % | $ 1.06 B | USA |
 |
Invitae Corporation
NVTA
|
320 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
124 M | $ 197.68 | 5.23 % | $ 19.5 B | USA |
 |
OPKO Health
OPK
|
642 M | $ 1.19 | - | $ 826 M | USA |
 |
Pacific Biosciences of California
PACB
|
43.9 M | $ 1.36 | 2.26 % | $ 408 M | USA |